查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1976586

動物血漿製品及衍生市場：按類型、按衍生類型、按最終用戶、按應用分類，全球預測（2026-2032年）

Animal Blood Plasma Products & Derivatives Market by Animal Type, Derivative Type, End-User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物血漿製品及衍生市場價值將達到 16.3 億美元，到 2026 年將成長至 17.5 億美元，到 2032 年將達到 27.9 億美元，複合年成長率為 7.99%。

主要市場統計數據
基準年 2025 16.3億美元
預計年份：2026年 17.5億美元
預測年份 2032 27.9億美元
複合年成長率 (%) 7.99%

對動物血漿製品及其衍生進行全面概述，為跨學科相關人員闡明科學、監管和供應鏈的優先事項。

動物血漿製品及其衍生領域與生命科學、食品加工、獸醫學和工業生物技術交叉融合，需要整合技術、監管和商業性觀點。本執行摘要系統地評估了該領域的當前趨勢，檢驗了影響競爭力和營運重點的因素，例如產品衍生、最終用途和供應鏈特徵。透過圍繞血清和纖維蛋白原等生物原料及其下游應用（包括細胞培養和營養）展開討論，本分析將這些原料置於傳統和新興價值鏈中。

技術進步、不斷變化的生物安全期望以及永續性壓力如何共同作用，重塑該領域的採購、產品一致性和供應商整合。

近年來，在技術和政策的推動下，供應商、製造商和終端用戶與動物血漿衍生產品的互動方式正發生著變革性的變化。細胞培養技術和組織工程平台的進步提高了對高品質血清和白蛋白的需求，促使供應商投資於可追溯性系統和更完善的品管流程。同時，加工和分離技術的創新提高了免疫球蛋白和纖維蛋白原製劑的一致性，使其在生物醫學研究和特定工業應用中得到更廣泛的應用。

了解 2025 年關稅調整如何重塑依賴專業生物原料的組織的採購、供應多樣化和庫存策略。

2025年美國關稅調整和貿易政策轉變將對整個供應鏈產生重大影響，改變依賴動物血漿衍生產品的公司的成本結構、供應商選擇和庫存策略。進口商和下游製造商正在採取應對措施，例如重新評估採購區域、加快供應商多元化計劃，並在可能的情況下優先考慮近岸外包。這些戰術性措施也伴隨著營運方面的變革，例如擴展供應商認證流程和擴大品質保證測試範圍，以確保符合法規和客戶要求。

我們透過深入的細分分析，將動物來源、衍生產品特性、最終用戶合規性和各種應用聯繫起來，從而製定客製化的採購和研發策略。

從動物種類、衍生產品種類、最終用戶和應用觀點進行細分分析，可以揭示不同的動態變化，從而為供應鏈設計和產品開發提供不同的見解。以動物種類（禽類、牛、羊、豬）為例，原料的可取得性、病原體篩檢程序以及文化和監管偏好等方面的差異會影響特定應用對原料的選擇。例如，牛源產品通常更適用於某些大批量應用，而當功能特性不同時，則會選擇豬源或羊源材料。同樣，對牛、纖維蛋白原、免疫球蛋白、血清白蛋白和凝血酶等衍生產品檢驗，可以發現每種衍生都有其獨特的加工、穩定性和品質保證要求，這些要求會影響儲存、處理和最終用途檢驗。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和物流現實決定了供應的連續性、合規性和供應商的選擇。

區域性研究揭示了地緣政治、物流和監管因素如何影響動物血漿衍生產品的獲取，並影響生產者和消費者的策略選擇。在美洲，接近性主要生物技術叢集和成熟的畜牧系統為科研級和工業應用提供了穩健的供應鏈。低溫運輸物流基礎設施和法律規範促進了區域內的跨境貿易。歐洲、中東和非洲地區呈現出複雜的格局，某些司法管轄區擁有嚴格的管理體制，而其他地區則具備新興的生產能力。這要求企業調整其合規策略，並投資與區域供應商建立夥伴關係，以確保產品品質和供應的連續性。

明確競爭優勢、品質投資和夥伴關係模式，並制定供應商策略，以創造獲得高純度、大批量衍生性商品的機會。

主要企業之間的競爭趨勢揭示了其差異化的策略策略。一些公司專注於生產用於生物醫學應用的高純度衍生物，而其他公司則優先考慮食品和飼料行業的規模和成本效益。市場定位受到品質保證系統、生物安全認證和供應鏈追蹤解決方案投資的影響，這些投資旨在滿足受監管終端用戶的需求。投資於專有加工技術和嚴格檢驗通訊協定的企業，對需要可重複性和完整文件記錄的製藥和組織工程客戶而言，正變得越來越有吸引力。

為領導者提供可操作且優先的行動方案，以加強價值鏈，整合研發和採購，並透過有針對性的供應商和產品策略創造價值。

產業領導者需要採取一系列切實可行的措施來增強韌性，使研發重點與供給能力保持一致，並在各個應用領域創造價值。首先，投資於整合來源檢驗、生物安全審計和分析驗證的供應商合格框架，將降低下游風險，並縮短受監管應用領域的品質保證時間。其次，在地域和動物種類上實現供應商網路多元化，將降低單一故障點的風險，同時確保獲得具有特定功能特性的衍生。第三，透過供應商協作測試和技術轉移通訊協定，協調採購和研發部門，將加速產品開發，並確保實驗室規模的性能能轉化為生產規模的可靠性。

透過結合相關人員訪談、技術整合和供應鏈映射的嚴謹、多方面的研究途徑，可以產生檢驗的營運建議。

支持這些研究結果的調查方法結合了與關鍵相關人員的對話、技術文獻整合以及供應鏈分析，以確保擁有可靠的證據基礎，從而為可操作的建議提供支持。關鍵對話包括與食品、製藥和動物醫藥行業各組織的採購經理、研發經理和品質保證專業人員進行結構化訪談，從而直接觀點採購限制、品質期望和物流實際情況。作為這些對話的補充，研究人員還查閱了技術文獻和行業指南，以明確每種衍生物的加工要求以及與各種最終用途相關的生物安全注意事項。

策略整合強調檢驗、供應商多元化和跨部門合作，以確保複雜生物供應鏈的韌性和技術性能。

總之，動物血漿製品及其衍生涉及的領域兼具科學的複雜性和操作的敏感性，因此需要採取綜合策略來管理品質、合規性和連續性。加工技術和應用科學的進步提高了人們對產品可追溯性和批間一致性的期望，而監管和貿易趨勢則加劇了對多元化和靈活採購的需求。積極主動地將嚴格的供應商篩選、策略性的地域多元化以及研發和採購部門之間的協作相結合的相關人員，將能夠更有效地降低風險，並抓住生物醫學、食品和獸醫領域的機遇。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 動物血漿製品及衍生市場：依動物類型分類

  • 鳥類
  • 牛
  • 羊
  • 豬

第9章 動物血漿製品及衍生市場：依衍生類型分類

  • 牛
  • 纖維蛋白原
  • 免疫球蛋白
  • 血清白蛋白
  • 長號

第10章：動物血漿製品及衍生市場：依最終用戶分類

  • 動物飼料生產商
  • 製藥公司
  • 獸醫

第11章 動物血漿製品及衍生市場：依應用領域分類

  • 動物飼料
  • 生物醫學研究
  • 細胞培養基
  • 食品加工
  • 營養補充品
  • 寵物食品業
  • 藥品和化妝品
  • 組織工程

第12章 動物血漿製品及衍生市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 動物血漿製品及衍生市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 動物血漿製品及衍生市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國：動物血漿製品及衍生市場

第16章 中國：動物血漿製品及衍生市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ACROBiosystems Inc.
  • Alfa Laval Corporate AB
  • ANZCO Foods Limited
  • Auckland BioSciences Ltd.
  • BioChemed Services
  • Biowest Company
  • Bovogen Biologicals Pty Ltd.
  • Canvax Reagents SL
  • Ebrator Biochemicals Inc.
  • Kraeber & Co. GmbH
  • Lake Immunogenics, Inc.
  • LAMPIRE Biological Laboratories, Inc.
  • Meiji Holdings Co., Ltd.
  • Merck KGaA
  • Pel-Freez, LLC
  • Rockland Immunochemicals, Inc.
  • Rocky Mountain Biologicals
  • Scripps Laboratories, Inc.
  • Sigma-Aldrich
  • TCS Biosciences Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0E2

The Animal Blood Plasma Products & Derivatives Market was valued at USD 1.63 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, with a CAGR of 7.99%, reaching USD 2.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.63 billion
Estimated Year [2026] USD 1.75 billion
Forecast Year [2032] USD 2.79 billion
CAGR (%) 7.99%

A comprehensive orientation to animal blood plasma products and derivatives that clarifies scientific, regulatory, and supply chain priorities for interdisciplinary stakeholders

The animal blood plasma products and derivatives landscape intersects life sciences, food processing, veterinary care, and industrial biotechnology, demanding a synthesis of technical, regulatory, and commercial perspectives. This executive summary introduces a structured appraisal of the sector's current dynamics, examining product derivatives, end-use applications, and supply chain characteristics that together shape competitive and operational priorities. By framing the conversation around biological inputs such as serum and fibrinogen as well as downstream applications spanning cell culture and nutrition, the analysis situates these materials within both traditional and emerging value chains.

This introduction highlights the necessity for stakeholders to balance scientific rigor with supply chain agility. Shifts in sourcing strategies, evolving quality expectations for biomedical and food-grade derivatives, and the cross-sectoral nature of demand underscore the importance of integrated decision-making. Consequently, the report emphasizes practical insights that align laboratory needs, regulatory compliance, and commercial imperatives, enabling organizations to prioritize investments in quality assurance, supplier relationships, and application-specific product development.

How technological advances, evolving biosafety expectations, and sustainability pressures are jointly reshaping sourcing, product consistency, and supplier integration in the sector

Recent developments have triggered transformative shifts in how suppliers, manufacturers, and end-users approach animal blood plasma derivatives, with technology and policy acting as primary accelerants. Advances in cell-culture techniques and tissue-engineering platforms have increased demand for high-quality serum and albumin, prompting suppliers to invest in traceability systems and enhanced quality control processes. Concurrently, innovations in processing and fractionation have improved the consistency of immunoglobulin and fibrinogen preparations, enabling wider adoption in both biomedical research and specialized industrial uses.

Regulatory evolution is reshaping procurement and validation approaches. Stricter documentation and biosafety expectations have elevated the importance of supplier vetting and provenance assurance, especially for applications with human-health implications. In parallel, sustainability considerations are prompting upstream changes in sourcing and waste management, incentivizing closed-loop practices and alternative sourcing strategies. These converging forces are driving a reconfiguration of supplier portfolios and encouraging vertical integration by firms seeking to secure raw materials and control quality. As a result, organizations that align R&D priorities with supplier capability and regulatory foresight are positioning themselves to capitalize on emerging technical opportunities while mitigating operational disruption.

Understanding how 2025 tariff adjustments reshaped procurement, supplier diversification, and inventory strategies for organizations dependent on specialized biological inputs

Tariff adjustments and trade policy shifts in the United States for 2025 have had material implications across the supply chain, altering cost structures, supplier selection, and inventory strategies for businesses reliant on animal blood plasma derivatives. Importers and downstream manufacturers have responded by reassessing sourcing geographies, accelerating supplier diversification plans, and increasing emphasis on nearshoring where feasible. These tactical responses have been accompanied by operational changes such as extended supplier qualification timelines and expanded quality assurance testing to ensure conformity with both regulatory and customer specifications.

The tariff environment has also influenced commercial negotiations and contractual terms, with buyers seeking more flexible pricing arrangements and suppliers negotiating longer-term contracts to stabilize revenue streams. Logistic patterns have adjusted in response, with companies reallocating inventory buffers across regional distribution centers to mitigate potential customs delays and cost volatility. For technology-driven users of serum and specialized proteins, procurement teams are balancing the need for high-certainty supply with cost management, often prioritizing validated suppliers with regional production capabilities. Overall, the tariff context has increased the premium on supply chain transparency, redundancy, and contractual agility to sustain research timelines and production continuity.

Deep segmentation insights that connect animal source, derivative characteristics, end-user compliance, and diverse applications to inform tailored sourcing and R&D strategies

Segmentation analysis reveals differentiated dynamics when observed through the lenses of animal type, derivative type, end-user, and application, each offering distinct implications for supply chain design and product development. When considering animal type-Avian, Bovine, Ovine, and Porcine-differences in source availability, pathogen screening protocols, and cultural or regulatory preferences influence which raw materials are favored for specific applications, with bovine-derived products commonly prioritized for certain high-volume applications and porcine or ovine materials selected where functional properties differ. In parallel, examining derivative types such as Fetal Bovine Serum, Fibrinogen, Immunoglobulin, Serum Albumin, and Thrombin clarifies that each derivative carries unique processing, stability, and quality assurance requirements that affect storage, handling, and end-use validation.

End-user segmentation across Food Manufacturers, Pharmaceutical Companies, and Veterinary sectors highlights divergent compliance frameworks and performance expectations: food processors emphasize food-safety certifications and allergen control, pharmaceutical firms prioritize traceability and regulatory documentation, and veterinary users balance efficacy with cost and shelf-life considerations. Application-driven distinctions-spanning Animal Feed, Biomedical Research, Cell Culture Media, Food Processing, Nutrition Supplements, Pet Food Industry, Pharmaceuticals & Cosmetics, and Tissue Engineering-illustrate variation in purity, functional specification, and value capture. For instance, biomedical research and cell culture demand stringent lot-to-lot consistency and contamination controls, while applications in animal feed and pet food tolerate broader specification ranges but require cost-efficient supply. Integrating these segmentation perspectives enables stakeholders to tailor sourcing, quality management, and product development roadmaps that reflect both technical constraints and commercial priorities.

Regional dynamics and logistical realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine supply continuity, compliance, and supplier choice

Regional insights illuminate how geopolitical, logistical, and regulatory factors shape access to animal blood plasma derivatives and influence strategic choices by producers and consumers. In the Americas, proximity to major biotech clusters and established animal agriculture systems supports robust supply chains for both research-grade and industrial applications, with infrastructure geared toward cold-chain logistics and regulatory oversight that facilitates cross-border trade within the region. Europe, Middle East & Africa presents a complex mosaic where stringent regulatory regimes in certain jurisdictions coexist with emerging production capacity in others, prompting companies to adapt compliance strategies and invest in regional supplier partnerships to assure quality and continuity.

Asia-Pacific has become increasingly pivotal, combining large-scale animal production capacity with expanding biomanufacturing and research activity. This region's logistical scale and cost efficiencies can offer advantages to global firms, though buyers must navigate heterogeneous regulatory landscapes and varying quality assurance norms. Across all regions, regional regulatory expectations, transport infrastructure, and source animal availability drive procurement decisions and strategic supplier alignment. Consequently, organizations that map regional strengths against application-specific requirements are better positioned to optimize supply continuity, reduce lead times, and manage compliance risk.

Competitive positioning and supplier strategies that delineate specialization, quality investment, and partnership models shaping access to high-purity and large-volume derivatives

Competitive dynamics among key companies reveal differentiated strategic approaches, with some firms focusing on specialization in high-purity derivatives for biomedical applications while others emphasize scale and cost-efficiency for food and feed segments. Market positions are influenced by investments in quality assurance systems, biosafety certifications, and supply chain traceability solutions that respond to the demands of regulated end-users. Organizations investing in proprietary processing technologies and rigorous validation protocols are increasingly attractive to pharmaceutical and tissue-engineering customers that require reproducibility and documentation.

Strategic partnerships and contract manufacturing relationships also shape competitive advantage. Firms that integrate forward into value-added services-such as custom formulation support, regulatory dossier assistance, and application-specific testing-tend to capture higher-margin relationships with research institutions and specialty manufacturers. Meanwhile, producers focused on commodity-grade derivatives leverage scale and cost management to maintain relevance in large-volume applications like animal feed and pet food. Observing these varied strategies enables stakeholders to benchmark potential suppliers against operational needs and to prioritize partners whose capabilities align with product specifications, compliance requirements, and long-term reliability.

Practical and prioritized actions for leaders to fortify supply chains, synchronize R&D with procurement, and capture value through targeted supplier and product strategies

Industry leaders must adopt a set of pragmatic, actionable steps to strengthen resilience, align R&D priorities with supply capabilities, and capture value across applications. First, investing in supplier qualification frameworks that integrate provenance verification, biosafety audits, and analytical validation will reduce downstream risk and shorten time-to-assurance for regulated applications. Second, diversifying supplier networks geographically and across animal sources can mitigate exposure to single-point disruptions while enabling access to derivatives with specific functional properties. Third, aligning procurement and R&D teams through joint supplier trials and technical transfer protocols will accelerate product development and ensure that laboratory-scale performance translates into production-scale reliability.

Additionally, companies should develop adaptive contracting approaches that balance price stability with flexibility for quality and volume adjustments, and they should incorporate inventory strategies that reflect application criticality rather than uniform stocking rules. For product developers, prioritizing formulations that accommodate broader input variability where possible will reduce sensitivity to supplier fluctuation. Finally, engaging proactively with regulators and standard-setting bodies to influence or anticipate compliance requirements will yield advantages in time-to-market and reduce rework. By operationalizing these recommendations, organizations can transform insight into resilient procurement, robust product pipelines, and sustained competitive differentiation.

A rigorous, multi-method research approach combining stakeholder interviews, technical synthesis, and supply chain mapping to generate validated operational recommendations

The research methodology underpinning these insights combines primary stakeholder engagement, technical literature synthesis, and supply chain analysis to ensure a robust evidence base that supports actionable recommendations. Primary engagement included structured interviews with procurement leads, R&D heads, and quality assurance professionals across food, pharmaceutical, and veterinary organizations, providing firsthand perspectives on sourcing constraints, quality expectations, and logistical realities. Complementing these dialogues, a review of technical literature and industry guidelines clarified derivative-specific processing requirements and biosafety considerations relevant to different end uses.

Supply chain mapping and trade-flow analysis were conducted to identify common bottlenecks and resilience levers, with attention to cold-chain demands, cross-border compliance, and supplier concentration. Triangulation of qualitative inputs with operational indicators allowed for the development of pragmatic recommendations focused on supplier qualification, contractual design, and inventory management. Throughout, methodological rigor was maintained by documenting assumptions, validating findings through multiple stakeholder perspectives, and prioritizing transparency in analytic steps to support reproducibility and confidence in the implications drawn for practitioners.

A strategic synthesis that emphasizes validation, supplier diversification, and cross-functional alignment to ensure resilience and technical performance in complex biological supply chains

In summary, animal blood plasma products and derivatives occupy a nexus of scientific complexity and operational sensitivity that requires integrated strategies to manage quality, compliance, and continuity. Advances in processing and application science have elevated expectations for traceability and lot consistency, while regulatory and trade dynamics have amplified the need for diversified sourcing and agile procurement. Stakeholders who proactively combine rigorous supplier qualification, strategic geographic diversification, and alignment between research and procurement functions will better mitigate risk and seize opportunities across biomedical, food, and veterinary arenas.

Ultimately, the sector rewards organizations that treat biological inputs not merely as commodities but as critical components of broader product and research ecosystems. By investing in validation, fostering strategic supplier relationships, and embedding regulatory foresight into procurement decisions, institutions can ensure operational resilience and maintain the technical performance that underpins end-user trust and innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Blood Plasma Products & Derivatives Market, by Animal Type

  • 8.1. Avian
  • 8.2. Bovine
  • 8.3. Ovine
  • 8.4. Porcine

9. Animal Blood Plasma Products & Derivatives Market, by Derivative Type

  • 9.1. Fetal Bovine Serum
  • 9.2. Fibrinogen
  • 9.3. Immunoglobulin
  • 9.4. Serum Albumin
  • 9.5. Thrombin

10. Animal Blood Plasma Products & Derivatives Market, by End-User

  • 10.1. Food Manufacturers
  • 10.2. Pharmaceutical Companies
  • 10.3. Veterinary

11. Animal Blood Plasma Products & Derivatives Market, by Application

  • 11.1. Animal Feed
  • 11.2. Biomedical Research
  • 11.3. Cell Culture Media
  • 11.4. Food Processing
  • 11.5. Nutrition Supplements
  • 11.6. Pet Food Industry
  • 11.7. Pharmaceuticals & Cosmetics
  • 11.8. Tissue Engineering

12. Animal Blood Plasma Products & Derivatives Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Blood Plasma Products & Derivatives Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Blood Plasma Products & Derivatives Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Animal Blood Plasma Products & Derivatives Market

16. China Animal Blood Plasma Products & Derivatives Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ACROBiosystems Inc.
  • 17.6. Alfa Laval Corporate AB
  • 17.7. ANZCO Foods Limited
  • 17.8. Auckland BioSciences Ltd.
  • 17.9. BioChemed Services
  • 17.10. Biowest Company
  • 17.11. Bovogen Biologicals Pty Ltd.
  • 17.12. Canvax Reagents S.L.
  • 17.13. Ebrator Biochemicals Inc.
  • 17.14. Kraeber & Co. GmbH
  • 17.15. Lake Immunogenics, Inc.
  • 17.16. LAMPIRE Biological Laboratories, Inc.
  • 17.17. Meiji Holdings Co., Ltd.
  • 17.18. Merck KGaA
  • 17.19. Pel-Freez, LLC
  • 17.20. Rockland Immunochemicals, Inc.
  • 17.21. Rocky Mountain Biologicals
  • 17.22. Scripps Laboratories, Inc.
  • 17.23. Sigma-Aldrich
  • 17.24. TCS Biosciences Ltd.
  • 17.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)